0001820190false0001820190sclx:CommonStockParValue00001PerShare2Member2026-11-112026-11-110001820190sclx:WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf40250PerShareMember2026-11-112026-11-1100018201902026-11-112026-11-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

_______________________

FORM 8-K
_______________________

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 11, 2026

_______________________

SCILEX HOLDING COMPANY
(Exact name of registrant as specified in its charter)

_______________________

Delaware
(State or other jurisdiction
of incorporation)

001-39852
(Commission
File Number)

92-1062542
(IRS Employer
Identification No.)

 

960 San Antonio Road, Palo Alto, California, 94303
(Address of principal executive offices, including zip code)

(650) 516-4310

Registrant’s telephone number, including area code

N/A
(Former Name or Former Address, if Changed Since Last Report)

_______________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

 

☐

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

 

☐

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

 

☐

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

(Title of each class)

(Trading Symbol)

(Name of exchange on which registered)

Common Stock, par value $0.0001 per share

SCLX

The Nasdaq Stock Market LLC

Warrants to purchase one share of common stock, each at an exercise price of $397.89

SCLXW

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 


 

Item 4.01. Changes in Registrant’s Certifying Accountant.

Dismissal of Independent Registered Public Accounting Firm

 

On November 11, 2026, the audit committee (the “Committee”) of the board of directors of Scilex Holding Company (the “Company”) approved the dismissal of BPM LLP (“BPM”) as the Company’s independent registered public accounting firm. The Company notified BPM of the dismissal on November 16, 2026.

 

The reports of BPM on the consolidated financial statements of the Company for the fiscal years ended December 31, 2025 and December 31, 2024 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles, except for an explanatory paragraph in each such report regarding substantial doubt about the Company’s ability to continue as a going concern. During the fiscal years ended December 31, 2025 and December 31, 2024, and the subsequent interim period through the date of BPM’s dismissal, there were no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K) with BPM on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of BPM, would have caused BPM to make reference to the subject matter of the disagreements in its reports covering such periods. In addition, no “reportable events,” as defined in Item 304(a)(1)(v) of Regulation S-K, occurred within the period of BPM’s engagement and the subsequent interim period preceding BPM’s dismissal.

 

The Company provided BPM with a copy of the foregoing disclosure and requested BPM to furnish the Company with a letter addressed to the Securities and Exchange Commission (the “SEC”) stating whether it agrees with the statements made herein. As of the filing of this Current Report on Form 8-K, BPM has not yet furnished the Company with a letter addressed to the SEC stating whether it agrees with the statements made herein. If BPM provides such a letter, the Company will file an amendment to this Current Report on Form 8-K to include a copy of such letter as an exhibit to such amendment.

 

Appointment of Pipara & Co LLP

 

On November 13, 2026, the Committee appointed and engaged Pipara & Co LLP (“Pipara”) as the Company’s independent registered public accounting firm for the quarter and nine months ending September 30, 2026 and the fiscal year ending December 31, 2026. Pipara’s appointment as the Company’s independent registered public accounting firm was subject to the completion of customary client acceptance procedures. Pipara currently serves as the independent registered public accounting firm of Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of the Company (“Semnur”).

 

During the Company’s two most recent fiscal years ended December 31, 2025 and December 31, 2024, and the subsequent interim period through the date of Pipara’s engagement, neither the Company nor anyone on its behalf consulted with Pipara regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and no written report or oral advice was provided to the Company that Pipara concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue, or (ii) any matter that was the subject of a disagreement within the meaning of Item 304(a)(1)(iv) of Regulation S-K or any reportable event within the meaning of Item 304(a)(1)(v) of Regulation S-K, in each case other than in connection with Pipara’s engagement as the independent registered public accounting firm of Semnur.

2

 


 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

SCILEX HOLDING COMPANY

 

 

 

 

By:

/s/ Stephen Ma

 

Name:

Stephen Ma

Date: November 17, 2026

Title:

Senior Vice President, Chief Operating Officer and Chief Financial Officer

 

3